MAPT and Alzheimer disease: While it has been found to diminish long-term potentiation (LTP) and memory consolidation in AD mice models through increased tau phosphorylation and disruption of the blood–brain barrier, it also facilitates the degradation of amyloid beta (Aβ) plaques, a major pathological driver in AD, thereby demonstrating both damaging and protective effects (18).